Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

What this episode covers

Visit https://www.peervoice.com/TQR860 to view the entire programme with slides. After completing “Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?”, participants will be able to: Recognise the rationale behind TROP2 as a therapeutic target in NSCLC; Recall the results of clinical trials assessing the safety and efficacy of TROP2-directed therapy across different types of NSCLC, including non-oncogene-addicted, EGFR-mutant and ALK-rearranged NSCLC; and Assess the clinical relevance of subgroup analyses evaluating the effect of TROP2-directed therapy in specific types of NSCLC (eg, EGFR-mutant NSCLC that has progressed after initial TKI therapy).

Distinct summary based on available episode metadata or transcript content.